Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin

References

• Abbott LaboratoriesSimcor (niacin extended-release/simvastatin) [prescribing information]2008 Accessed May 5, 2008
   Google Scholar
• PaoliniJFMitchelYBReyesREffects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemiaAm J Cardiol20081016253018308010
   PubMed Web of Science ®Google Scholar
• LaiEWenningLCrumleyTPharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonistNature Clin Pharmacol Ther2008838407
   PubMed Web of Science ®Google Scholar
• RubicTTrottmannMLorenzRStimulation of CD36 and the key effector of reverse choelsterol transport ATP-binding cassette A1 in monocytoid cells by niacinBiochem Pharmacol200467411915037193
   PubMed Web of Science ®Google Scholar
• Oxford University by the Clinical Trial Service Unit. Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE), June 1, 2006 press release.
   Google Scholar
• RobinsonJDavidsonMCombination therapy with ezetimibe and simvastatin to acheive aggressive LDL reductionExpert Rev Cardiovasc Ther200644617616918265
   PubMedGoogle Scholar
• The Search Collaborative GroupSLCO1B1 variants and statin-induced myopathy – A genomewide studyN Engl J Med20083597899918650507
   PubMed Web of Science ®Google Scholar
• RobinsonJGDavidsonMHInvestigational drugs targeting HDL-C metabolism and reverse cholesterol transportFut Lipidol20072285301
   Web of Science ®Google Scholar
• SuryadevaraRSKarasRHKuvinJTUse of extended-release niacin in clinical practiceFuture Lipidology200831916
   Web of Science ®Google Scholar
• Lamon-FavaSDiffenderferMRBarrettPHRExtended-release niacin alters the metabolism of plasma apolipoprotein (apo) A-I and apoB-containing lipoproteinsArterioscler Thromb Vasc Biol2008281672818566298
   PubMed Web of Science ®Google Scholar
• ZhangL-HKamannaVSZhangMCKashyapMLNiacin inhibits surface expression of ATP synthase {beta} chain in HepG2 cells: implications for raising HDLJ Lipid Res200849119520118316796
   PubMed Web of Science ®Google Scholar
• BallantyneCDavidsonMHMcKenneyJMKellerLHBajorunasDRKarasRHComparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvstatin 80 mg montherapy: the SEACOAST II (high dose) studyJ Clin Lipidol200827990
   PubMed Web of Science ®Google Scholar
• BallantyneCMDavidsonMHMcKenneyJKellerLHBajorunasDRKarasRHComparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I Study)Am J Cardiol200810114283618471454
   PubMed Web of Science ®Google Scholar
• KarasRHKashyapMLKnoppRHKellerLHBajorunasDRDavidsonMHLong-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: The OCEANS studyAm J Cardiovasc Drugs20088698118422390
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education PanelThird Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final ReportCirculation2002106314342112485966
   PubMed Web of Science ®Google Scholar
• GuytonJRBaysHESafety considerations with niacin therapyAm J Cardiol2007996 Suppl 1S22S31
   Google Scholar
• Abbott LaboratoriesNiaspan (niacin extended-release) [prescribing information]32008 http://www.rxabbott.com/pdf/niaspan.pdf Accessed August 2008
   Google Scholar
• DavidsonMHNiacin use and cutaneous flushing: Mechanisms and strategies for preventionAm J Cardiol20081018 Suppl 1S14S9
   Google Scholar
• CefaliESimmonsPStanekEMcGovernMKisslingCAspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulationInt J Clin Pharmacol Ther200745788817323787
   PubMed Web of Science ®Google Scholar
• DunnRFordMRindoneJKwiecinskiFLow-dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administrationAm J Ther199524788011850694
   PubMedGoogle Scholar
• Merck and CoZocor (simvastatin) [prescribing information]2008 http://www.merck.com/product/usa/pi_circulars/z/zocor/zocor_pi.pdf Accessed June 2008
   Google Scholar
• DavidsonMRobinsonJGSafety of aggressive lipid managementJ Am Coll Cardiol20074917536217466224
   PubMed Web of Science ®Google Scholar
• CohenDAnaniaFChalasaniNAn assessment of statin safety by hepatologistsAm J Cardiol2006978 Suppl 1S7781
   PubMedGoogle Scholar
• ThompsonPDClarksonPMRosensonRSAn assessment of statin safety by muscle expertsAm J Cardiol2006978 Suppl 1S69S76
   Google Scholar
• Abbott LaboratoriesAdvicor (extended-release niacin) [prescribing information]82007 http://www.rxabbott.com/pdf/advicor.pdf. Accessed June 2008
   Google Scholar
• Alsheikh-AliAAKarasRHThe safety of niacin in the US Food and Drug Administration Adverse Event Reporting databaseAm J Cardiol20081018 Suppl 1S9S13
   PubMedGoogle Scholar
• Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trialLancet200236072212114036
   PubMed Web of Science ®Google Scholar
• GrahamDJStaffaJAShatinDIncidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugsJAMA200429225859015572716
   PubMed Web of Science ®Google Scholar
• PrueksaritanontTZhaoJJMaBMechanistic studies on metabolic interactions between gemfibrozil and statinsJ Pharmacol Exp Ther200230110425112023536
   PubMed Web of Science ®Google Scholar
• GoosenTCBaumanJNDavisJAAtorvastatin glucuronidation is minimally and non-selectively inhibited by the fibrates gemfibrozil, fenofibrate and fenofibric acidDrug Metab Dispos2007 Epub April 30, 2007:dmd.107.015230.
   PubMed Web of Science ®Google Scholar
• NeuvonenPJNiemiMBackmanJTDrug interactions with lipid-lowering drugs: Mechanisms and clinical relevanceClin Pharmacol Ther2006805658117178259
   PubMed Web of Science ®Google Scholar
• ElamMBHunninghakeDBDavisKBEffect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: The ADMIT Study: A randomized trialJAMA200028412637010979113
   PubMed Web of Science ®Google Scholar
• CannerPLFurbergCDTerrinMLMcGovernMEBenefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)Am J Cardiol200595254715642562
   PubMed Web of Science ®Google Scholar
• CannerPLFurbergCDMcGovernMEBenefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project)Am J Cardiol200697477916461040
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) CollaboratorsEfficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet200536612677816214597
   PubMed Web of Science ®Google Scholar
• RobinsonJGSmithBMaheshwariNSchrottHPleiotropic effects of statins: Benefit beyond cholesterol reduction? A meta-regression analysisJ Am Coll Cardiol20054618556216286171
   PubMed Web of Science ®Google Scholar
• GrundySMCleemanJIMerzCNBImplications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelinesCirculation20041102273915249516
   PubMed Web of Science ®Google Scholar
• SmithJSCAllenJBlairSNAHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood InstituteJ Am Coll Cardiol2006472130916697342
   PubMed Web of Science ®Google Scholar
• LaRosaJCGrundySMWatersDDIntensive lipid lowering with atorvastatin in patients with stable coronary diseaseN Engl J Med200535214253515755765
   PubMed Web of Science ®Google Scholar
• AstraZeneca PharmaceuticalsCrestor (rosuvstatin calcium) [prescribing information]12007 http://www.astrazeneca-us.com/pi/crestor.pdf. Accessed February 2007
   Google Scholar
• Pfizer IncLipitor (atorvastatin calcium) [prescribing information]112007 http://www.pfizer.com/files/products/uspi_lipitor.pdf. Accessed June 2008
   Google Scholar
• JonesPHDavidsonMHSteinEAComparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)Am J Cardiol2003921526012860216
   PubMed Web of Science ®Google Scholar
• Daiichi SankyoIWelchol (coleselvelam hydrochloride) [prescribing information]122005 http://www.welchol.com/pdf/Welchol_PI.pdf. Accessed May 5, 2008
   Google Scholar
• WagnerAMJorbaOBonetROrdonez-LlanosJPerezAEfficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemiaJ Clin Endocrinol Metab2003883212712843167
   PubMed Web of Science ®Google Scholar
• AthyrosVGPapageorgiouAAAthyrouVVDemitriadisDSKontopoulosAGAtorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemiaDiab Care2002251198202
   PubMed Web of Science ®Google Scholar
• DurringtonPNTuomilehtoJHamannAKallendDSmithKRosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemiaDiab Res Clin Pract20046413751
   PubMed Web of Science ®Google Scholar
• KasteleinJJPAkdimFStroesESGSimvastatin with or without ezetimibe in familial hypercholesterolemiaN Engl J Med200835814314318376000
   PubMed Web of Science ®Google Scholar
• SmildeTJvan WissenSAwollersheimHTripMDKasteleinJJPStalenhoefAFHEffect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trialLancet20013575778111558482
   PubMed Web of Science ®Google Scholar
• UnderhillHRYuanCZhaoX-QEffect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: A high-resolution magnetic resonance imaging trialAm Heart J2008155584.e581584e58818294500
   PubMed Web of Science ®Google Scholar
• JohnsonHMDouglasPSSrinivasanSRPredictors of carotid intima-media thickness progression in young adults: The Bogalusa Heart StudyStroke200738900517272779
   PubMed Web of Science ®Google Scholar
• van WissenSSmildeTJTripMDStalenhoefAFHKasteleinJJPLong-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemiaAm JCardiol200595264615642565
   PubMed Web of Science ®Google Scholar
• LoftusPMerck halts study of experimental cholesterol drugWall Street Journal2008522
   Google Scholar
• RosseboABPedersenTRBomanKIntensive lipid lowering with simvastatin and ezetimibe in aortic stenosisN Engl J Med200835913435618765433
   PubMed Web of Science ®Google Scholar
• PetoREmbersonJLandrayMAnalyses of cancer data from three ezetimibe trialsN Engl J Med200835913576618765432
   PubMed Web of Science ®Google Scholar
• KasteleinJJPvan der StiegWHolmeILipids, apoliproteins, and their ratios in relation to cardiovascular events with statin treatmentCirculation20081173002918519851
   PubMed Web of Science ®Google Scholar
• BarterPJCaulfieldMErikssonMEffects of torcetrapib in patients at high risk for coronary eventsN Engl J Med200735721092217984165
   PubMed Web of Science ®Google Scholar
• PedersenTRFaergemanOKasteleinJJPHigh-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL Study: A randomized controlled trialJAMA200529424374516287954
   PubMed Web of Science ®Google Scholar
• RobinsonJGShould we use PPAR agonists to reduce cardiovascular risk?PPAR Res2008doi:10.1155/2008/891425
   PubMed Web of Science ®Google Scholar
• BarterPGottoAMLaRosaJCHDL cholesterol, very low levels of LDL cholesterol, and cardiovascular eventsN Engl J Med200735713011017898099
   PubMed Web of Science ®Google Scholar
• MozaffarianDWilsonPWFKannelWBBeyond established and novel risk factors: Lifestyle risk factors for cardiovascular diseaseCirculation20081173031818541753
   PubMed Web of Science ®Google Scholar
• RobinsonJGStoneNJAntiatherosclerotic and antithrombotic effects of omega-3 fatty acidsAm J Cardiol2006984 Suppl 13949
   Google Scholar
• MarcovinaSMKoschinskyMLAlbersJJSkarlatosSReport of the National Heart, Lung, and Blood Institute workshop on lipoprotein(a) and cardiovascular disease: Recent advances and future directionsClin Chem20034917859614578310
   PubMed Web of Science ®Google Scholar
• Coronary Drug ProjectClofibrate and niacin in coronary heart diseaseJAMA1975231360801088963
   PubMed Web of Science ®Google Scholar
• BrownBGZhaoX-QChaitASimvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary diseaseN Engl J Med200134515839211757504
   PubMed Web of Science ®Google Scholar
• BrownMDPBGBardsleyMDJPoulinBSDHillgerPLAModerate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery diseaseAm J Cardiol19978011159230143
   PubMed Web of Science ®Google Scholar
• Cashin-HemphillLMackWPogodaJSanmarcoMAzenSBlankenhornDBeneficial effects of colestipol-niacin on coronary atherosclerosis: A 4-year follow-upJAMA1990264301372243429
   PubMed Web of Science ®Google Scholar
• TaylorALeeHSullenbergerLThe effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3Curr Opin Med Res Opin200622224350
   PubMed Web of Science ®Google Scholar
• TaylorAJSullenbergerLELeeHJLeeJKGraceKAArterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statinsCirculation20041103512715537681
   PubMed Web of Science ®Google Scholar
• RobinsonJGBakrisGTornerJStoneNJWallaceRIs it time for a cardiovascular primary prevention trial in the elderlyStroke2007384415017194877
   PubMed Web of Science ®Google Scholar
• RobinsonJGStoneNJIdentifying patients for aggressive cholesterol lowering: The risk curve conceptAm J Cardiol2006981405817134640
   PubMed Web of Science ®Google Scholar